Table 5. Assessed fecal microbiota in healthy subjects at baseline and after four and eight weeks of daily treatment with B. infantis 35624 and after 2 weeks of post-supplementation follow-up.
| Microbiota | Study Visit | Treatment |
|---|---|---|
| |
|
B. infantis 35624 (log 10 ng DNA g−1) |
| |
|
Mean (SE) |
| Clostridium perfringens gp. |
Baseline |
1.21 (0.135) |
| |
Week 4 |
1.50 (0.102) |
| |
Week 8 |
1.42 (0.102) |
| |
Follow-up |
1.32 (0.103) |
| Enterococcus spp |
Baseline |
2.24 (0.110) |
| |
Week 4 |
2.31 (0.079) |
| |
Week 8 |
1.98 (0.093) |
| |
Follow-up |
2.18 (0.098) |
| Bacteroides-Prevotella-Porphymonas |
Baseline |
5.73 (0.039) |
| |
Week 4 |
5.81 (0.030) |
| |
Week 8 |
5.68 (0.029) |
| Follow-up | 5.74 (0.034) |
Healthy subjects received B. infantis 35624 supplementation for eight weeks. No supplement was administered at baseline or during follow-up (weeks 9 and 10).